Photo of Lara E. Davis, M.D.

Lara E. Davis M.D.

Dr. Davis received her undergraduate degree at Wellesley College and her M.D. from OHSU.  She returned to the East Coast for residency training before completing her oncology training at OHSU.  Dr. Davis is board-certified in both Medical Oncology and Pediatric Hematology/Oncology.

Education

  • M.D., Oregon Health & Science University, Portland Oregon 2005
  • Residency:

    • Harvard - combined internal medicine-pediatrics residency program, 2005-2009
  • Fellowship:

    • Medical oncology and pediatric hematology/oncology, Oregon Health & Science University, 2009-2013
  • Certifications:

    • American Board of Internal Medicine, 2009

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "Erratum" Nature Medicine July 7 2015
  • "A new approach for prediction of tumor sensitivity to targeted drugs based on functional data" BMC Bioinformatics July 29 2013
  • "Personalized cancer care" Pediatric Blood and Cancer July 15 2012
  • "Preoperative Therapy for Extremity Soft Tissue Sarcomas" Current Treatment Options in Oncology June 16 2015
  • "Overcoming autopsy barriers in pediatric cancer research" Pediatric Blood and Cancer February 2013
  • "A case study of personalized therapy for osteosarcoma" Pediatric Blood and Cancer August 2013
  • "An integrated approach to anti-cancer drug sensitivity prediction" IEEE/ACM Transactions on Computational Biology and Bioinformatics November 1 2014
  • "Combination therapy design for targeted therapeutics from a drug-protein interaction perspective"   2012
  • "Analyzing pathway design from drug perturbation experiments"   2012
  • "Inference of dynamic biological networks based on responses to drug perturbations" Tijdschrift voor Urologie January 17 2014
  • "Functionally defined therapeutic targets in diffuse intrinsic pontine glioma" Nature Medicine May 4 2015
  • "An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101" Cancer Discovery October 1 2015
  • "Clinical trial enrollment of adolescents and young adults with sarcoma" Cancer September 15 2017
  • "Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species" Oncotarget  2017
  • "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028)" The Lancet Oncology November 1 2017
  • "Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas" Cell November 2 2017
  • "Osteosarcoma, chondrosarcoma, and chordoma" Journal of Clinical Oncology January 10 2018
  • "Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas" Annals of Surgical Oncology April 1 2018
  • "CDK4/6 Inhibitors" Cancer Cell July 9 2018
  • "Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults" Cancer Medicine January 1 2018
  • "Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment" Radiology Case Reports August 1 2018
  • "Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma" Molecular Cancer Research March 1 2019
  • "Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma" Journal of Clinical Oncology June 1 2019

Additional information

Edit profile